Skip to main content

Advertisement

Table 4 Serum clinical safety markers, part I

From: Safety of TeaCrine®, a non-habituating, naturally-occurring purine alkaloid over eight weeks of continuous use

Variable T1 T2 T3 Time*group Time*group*gender
Cholesterol (mg/dL)
 PLA 155 ± 37 154 ± 34 161 ± 32 Time p = 0.07 G*T*Ge p = 0.38
 LD 151 ± 28 150 ± 26 160 ± 28 G*T p= 0.001
 HD 174 ± 33 162 ± 33 160 ± 32
HDL (mg/dL)
 PLA 49 ± 10 51 ± 12 55 ± 12 Time p = 0.08 G*T*Ge p = 0.99
 LD 47 ± 11 50 ± 12 51 ± 12 G*T p = 0.16
 HD 53 ± 16 49 ± 15 52 ± 16
LDL (mg/dL)
 PLA 89.4 ± 28.9 83.4 ± 28.9 87.7 ± 23.9 Time p= 0.001 G*T*Ge p = 0.38
 LD 85.0 ± 19.8 78.9 ± 17.8 86.9 ± 22.2 G*T p= 0.024
 HD 103.0 ± 22.1 89.3 ± 20.5 89.2 ± 19.9
Cholesterol/HDL
 PLA 3.3 ± 0.9 3.1 ± 0.9 3.0 ± 0.8 Time p = 0.19 G*T*Ge p = 0.48
 LD 3.2 ± 0.8 3.0 ± 0.8 3.2 ± 0.9 G*T p = 0.77
 HD 35 ± 0.9 3.3 ± 0.9 3.3 ± 0.9
Triglycerides (mg/dL)
 PLA 67 ± 25 77 ± 31 73 ± 31 Time p = 0.21 G*T*Ge p = 0.73
 LD 80 ± 45 93 ± 50 97 ± 50 G*T p = 0.63
 HD 87 ± 39 92 ± 40 83 ± 36
Glucose (mg/dL)
 PLA 86 ± 8 86 ± 8 86 ± 6 Time p = 0.14 G*T*Ge p = 0.44
 LD 87 ± 7 86 ± 8 90 ± 8 G*T p = 0.55
 HD 84 ± 9 86 ± 9 86 ± 7
  1. Abbreviations: PLA Placebo, LD Theacrine Low Dose, HD Theacrine High Dose, G Group, T Time, Ge Gender
  2. Symbols: , different from corresponding T1 value (p < 0.05). Items in bold indicate a significant effect (p < 0.05) was observed